IL155275A0 - Lactam compound - Google Patents

Lactam compound

Info

Publication number
IL155275A0
IL155275A0 IL15527501A IL15527501A IL155275A0 IL 155275 A0 IL155275 A0 IL 155275A0 IL 15527501 A IL15527501 A IL 15527501A IL 15527501 A IL15527501 A IL 15527501A IL 155275 A0 IL155275 A0 IL 155275A0
Authority
IL
Israel
Prior art keywords
lactam compound
lactam
compound
Prior art date
Application number
IL15527501A
Other languages
English (en)
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of IL155275A0 publication Critical patent/IL155275A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
IL15527501A 2000-11-17 2001-11-02 Lactam compound IL155275A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (fr) 2000-11-17 2001-11-02 Compose lactame

Publications (1)

Publication Number Publication Date
IL155275A0 true IL155275A0 (en) 2003-11-23

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15527501A IL155275A0 (en) 2000-11-17 2001-11-02 Lactam compound

Country Status (33)

Country Link
US (1) US20040248878A1 (fr)
EP (1) EP1353910B1 (fr)
JP (1) JP4116431B2 (fr)
KR (1) KR20030045194A (fr)
CN (2) CN101624372A (fr)
AR (1) AR031356A1 (fr)
AT (1) ATE362919T1 (fr)
AU (2) AU2002224321B2 (fr)
BR (1) BR0115424A (fr)
CA (1) CA2425497C (fr)
CY (1) CY1106682T1 (fr)
CZ (1) CZ20031340A3 (fr)
DE (1) DE60128587T2 (fr)
DK (1) DK1353910T3 (fr)
DZ (1) DZ3454A1 (fr)
EA (1) EA006919B1 (fr)
EC (1) ECSP034598A (fr)
ES (1) ES2286162T3 (fr)
HR (1) HRP20030385A2 (fr)
HU (1) HUP0301862A3 (fr)
IL (1) IL155275A0 (fr)
MX (1) MXPA03004250A (fr)
MY (1) MY141607A (fr)
NO (1) NO325217B1 (fr)
PE (1) PE20020798A1 (fr)
PL (1) PL211018B1 (fr)
PT (1) PT1353910E (fr)
SK (1) SK287794B6 (fr)
SV (1) SV2003000741A (fr)
TW (1) TWI235151B (fr)
UA (1) UA77165C2 (fr)
WO (1) WO2002040451A2 (fr)
ZA (1) ZA200303411B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
CA2509413C (fr) 2002-12-20 2012-05-01 Glaxo Group Limited Derivatifs de benzazepine pour le traitement de troubles neurologiques
ES2295816T3 (es) 2003-01-14 2008-04-16 Arena Pharmaceuticals, Inc. Derivados arilo y heteroarilo 1,2,3-trisustituidos como moduladores del metabolismo, y profilaxis y tratamiento de transtornos relacionados con los mismos, tales como la diabetes y la hiperglucemia.
KR20070116865A (ko) 2005-04-08 2007-12-11 다이이찌 산쿄 가부시키가이샤 피리딜메틸설폰 유도체
EP1985615A4 (fr) 2006-01-31 2011-12-14 Api Corp Procédé de production de benzazépinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
WO2012040279A1 (fr) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
WO2014171434A1 (fr) 2013-04-19 2014-10-23 国立大学法人岡山大学 Agent de traitement des troubles cognitifs, basé sur la protéine bêta-amyloïde, agent thérapeutique contre la maladie d'alzheimer et procédé de traitement et procédé d'analyse pathologique correspondants
NZ734220A (en) 2015-01-06 2022-01-28 Arena Pharm Inc Methods of treating conditions related to the s1p1 receptor
MA42807A (fr) 2015-06-22 2018-07-25 Arena Pharm Inc Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
KR20190116416A (ko) 2017-02-16 2019-10-14 아레나 파마슈티칼스, 인크. 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
KR20230005163A (ko) 2020-03-26 2023-01-09 씨젠 인크. 다발성 골수종 치료 방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129820A0 (en) * 1996-12-23 2000-02-29 Elan Pharm Inc Cycloalkyl lactam lactone and related compounds as beta-amyloid peptide release inhibitors
WO1999067219A1 (fr) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Composes destines a inhiber la liberation et/ou la synthese du peptide beta-amyloide
WO2001034571A1 (fr) * 1999-11-09 2001-05-17 Eli Lilly And Company COMPOSES CONTENANT DES β-ACIDES AMINES UTILES POUR INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE β-AMYLOIDE

Also Published As

Publication number Publication date
AU2432102A (en) 2002-05-27
ES2286162T3 (es) 2007-12-01
EA006919B1 (ru) 2006-04-28
DE60128587D1 (de) 2007-07-05
CZ20031340A3 (cs) 2004-06-16
ATE362919T1 (de) 2007-06-15
ZA200303411B (en) 2004-08-02
WO2002040451A2 (fr) 2002-05-23
NO20032215D0 (no) 2003-05-15
ECSP034598A (es) 2003-06-25
CN101624372A (zh) 2010-01-13
PL211018B1 (pl) 2012-03-30
MXPA03004250A (es) 2003-09-22
US20040248878A1 (en) 2004-12-09
HUP0301862A3 (en) 2007-09-28
BR0115424A (pt) 2003-10-21
MY141607A (en) 2010-05-31
AR031356A1 (es) 2003-09-17
JP2004521084A (ja) 2004-07-15
CN1575282A (zh) 2005-02-02
KR20030045194A (ko) 2003-06-09
AU2002224321B2 (en) 2006-10-19
SV2003000741A (es) 2003-01-13
CN100516047C (zh) 2009-07-22
CA2425497C (fr) 2010-08-17
EA200300579A1 (ru) 2003-12-25
NO325217B1 (no) 2008-02-25
DZ3454A1 (fr) 2002-05-23
NO20032215L (no) 2003-07-16
HUP0301862A2 (hu) 2003-09-29
PE20020798A1 (es) 2002-09-06
JP4116431B2 (ja) 2008-07-09
TWI235151B (en) 2005-07-01
WO2002040451A3 (fr) 2003-08-28
DK1353910T3 (da) 2007-09-10
CY1106682T1 (el) 2012-05-23
CA2425497A1 (fr) 2002-05-23
PT1353910E (pt) 2007-08-20
HRP20030385A2 (en) 2003-08-31
SK287794B6 (sk) 2011-10-04
DE60128587T2 (de) 2008-01-31
UA77165C2 (en) 2006-11-15
SK5432003A3 (en) 2004-09-08
PL360991A1 (en) 2004-09-20
EP1353910B1 (fr) 2007-05-23
EP1353910A2 (fr) 2003-10-22

Similar Documents

Publication Publication Date Title
AU4319202A (en) Lactam compound
EP1349851A4 (fr) Composes
IL155275A0 (en) Lactam compound
AU2405002A (en) Dehalogeno compounds
GB0113781D0 (en) Compound
SI1297053T1 (en) Polyamides
PH12001001591B1 (en) Polyamides
GB0027046D0 (en) Compound
GB0019377D0 (en) Compound
GB0004317D0 (en) Compound
GB0018529D0 (en) Compound
GB0018040D0 (en) Compound
GB0031061D0 (en) Novel compound
HUP0402189A3 (en) Intermediate compounds
SI1297052T1 (sl) Poliamidi
GB0003140D0 (en) Compounds
GB0007404D0 (en) Compounds
GB0003608D0 (en) Compounds
GB0003600D0 (en) Compounds
GB0003599D0 (en) Compounds
GB0003598D0 (en) Compounds
GB0006800D0 (en) Compounds
GB0006797D0 (en) Compounds
GB0003631D0 (en) Compounds
GB0002969D0 (en) Compounds